ReviewWorld journal of stem cells2020
Perspectives on mesenchymal stem/progenitor cells and their derivates as potential therapies for lung damage caused by COVID-19.
Review in World journal of stem cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.BMC infectious diseases · 2021Pooled it
- Mesenchymal stem cell application in pulmonary disease treatment with emphasis on their interaction with lung-resident immune cells.Frontiers in immunology · 2024Review
- Key Role of Mesenchymal Stromal Cell Interaction with Macrophages in Promoting Repair of Lung Injury.International journal of molecular sciences · 2023Review
- Review
- Adipose Tissue-Derived Mesenchymal Stem/Stromal Cells and Their Contribution to Angiogenic Processes in Tissue Regeneration.International journal of molecular sciences · 2022Review
- The Potential Contribution of Biopolymeric Particles in Lung Tissue Regeneration of COVID-19 Patients.Polymers · 2021Review
- Evolutionary warning system for COVID-19 severity: Colony predation algorithm enhanced extreme learning machine.Computers in biology and medicine · 2021Article
- Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm.Stem cells (Dayton, Ohio) · 2021Article
- Stem cell therapies and benefaction of somatic cell nuclear transfer cloning in COVID-19 era.Stem cell research & therapy · 2021Review
- Cryo-Temperature Pretreatment Increases the Pro-Angiogenic Capacity of Three-Dimensional Mesenchymal Stem CellsCell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The new coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which emerged in December 2019 in Wuhan, China, has reached worldwide pandemic proportions, causing coronavirus disease 2019 (COVID-19). The clinical manifestations of COVID-19 vary from an asymptomatic disease course to clinical symptoms of acute respiratory distress syndrome and severe pneumonia. The lungs are the primary organ affected by SARS-CoV-2, with a very slow turnover for renewal. SARS-CoV-2 enters the lungs
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.